Some nice posts yesterday by BKC on science and Cityslicker et al on the business side. It was nice to take a break from the self flagellation and DM bashing for a moment. 

SFran’s idea of a fireside chat with DM would be awesome, but we all know there is zero to .0000001 percent chance of that happening. Most CEO’s seem to have disdain for the retail side and DM has not shown he is any different. 

However, lets pretend he was given truth serum, there are hundreds of questions this board would ask, but how about answers to these questions: 

1. There has been criticism the BETonMACE trial was underpowered. Did the science advisors express this concern beforehand and it was purely an economic decision or were they convinced the trial would still meet the topline criteria as structured?
2. How close has RVX been in the past to an actual deal with a BP? Is the issue RVX’s internal valuation vs BP, the fact BP knows RVX has financing and market optics issues, the fact as City Slicker says that epigenetics is still new field or the failed trials give pause for concern?
3. What’s up with the recent PP announcement after two weeks before saying you expected a partnership deal by year end? Is this protective or strategic? Is a partnership deal with BP still on the table?
4. Was there ever any suggestion or urging by the key shareholders or BOD to step aside as CEO and stay on as an advisor while RVX hired a past Pharma CEO who has done deals and is looking for a short term gig to entertain themselves for an incentive laden contract?
5. What the heck is Hepalink doing here? They have invested millions but appear happy to let you run things on a seemingly last second scramble basis for years? (Some posters have intimated you are just dragging this out for your own personal benefit, not sure I believe this, but if so, why is Hepa allowing this). Why have they not stepped in and hired the above experienced Pharma CEO? Do they want to takeover RVX at low price, hold the Chinese rights, make a massive profit or what?
6. Does Dart pay attention to this investment or is it one of his hundred small cap plays and if it works it works, if not, a good tax loss?
7. Why the disconnect from the expected stock price increase management expected on the BTD designation from the market? Were you actually shocked this occurred given RVX’s past track record?
8. How much is Zenith tied to any partnership/sale negotiations or are they kept totally separate?
9. Any consideration of extending the June 2021 warrants if need be to reward those who helped keep RVX financed?
10. Was a US listing always dependant upon a successful trial that provided a higher stock price? Was a reverse split ever considered when the sp was in the $3 range?
11. Are the retail shareholders out to lunch and don’t understand the real issues? If so, what are those?  

I am sure others can add another 50 questions. Happy Thanksgiving and may this saga come to a least a partnership conclusion by the end of the year although, as we all know, what has been said and done, never seem to intersect :(